Browse studies
Find your next paid study
3 recruiting studies matching your filters
Phase 1
A Phase 1 Study Evaluating the Safety and Preliminary Efficacy of ALLO-329, a Dual Anti-CD19/Anti-CD70 Allogeneic CAR T Cell Product in Autoimmune Disease
This is a first-in-human, single-arm, open-label study evaluating the safety, tolerability, and preliminary efficacy of ALLO-329 in adults with autoimmune dise…
Systemic Lupus Erythematosus (With and Without Nephritis)Idiopathic Inflammatory MyopathySystemic Sclerosis
Allogene TherapeuticsNCT07085104
Phase 2
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy
RESET-Myositis: Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects with Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathi…
Idiopathic Inflammatory MyopathyDermatomyositisAnti-Synthetase Syndrome+5 more
Cabaletta BioNCT06154252
Phase 1
A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Autoimmune Diseases: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, or Rheumatoid Arthritis (Breakfree-1)
The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory auto…
Systemic Lupus ErythematosusIdiopathic Inflammatory MyopathySystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyNCT05869955